The HIV/AIDS epidemic remains one of the major global health challenges of al time. Currently over 42 million people are living with HIV and, without access to therapy, most will die of AIDS in the next 2 decades. Since 1996, potent antiretroviral therapies in the developed world have made HIV a chronic, manageable disease. For poorer settings, where 95% of the 5 million annual incident infections occur, access to interventions to treat or prevent HIV are limited. There is a great need for both innovative HIV preventive research, that includes adolescent populations, as well as therapeutic research that strives to reduce the burden of disease in poor communities. Based in South Africa, the University of the Witwatersrand's Perinatal HIV Research Unit and its key partner, the Respiratory and Meningeal Pathogens Research Unit are joint applicants in a Soweto Clinical Trials Unit (CTU).This CTU together with four clinical trial research sites (CRS) address the high priority areas of the four Network Leadership Groups of the HVTN, IMPAACT, ACTG and HPTN. This team brings extensive scientific and clinical trial experience to the new network leadership groups, has a long history of community engagement, and has developed previously disadvantaged researchers. As experienced trialists in the HVTN, they propose to contribute to the HVTN's priority research agenda by leading vaccine development teams, conducting phase l/ll trials, """"""""proof of concept"""""""" trials in high risk populations and prioritizing adolescent involvement in vaccine research;as pioneers in the field of PMTCT and pediatric therapeutic and co-morbidity research, they will be instrumental in achieving the IMPAACT's agenda in optimizing PMTCT strategies and treatment strategies for children;as investigators in ground breaking prevention research that prioritizes gender and community issues, they will be able to address the HPTN's research priorities;and as researchers involved in HIV therapeutic trials in adults since 1996, in industry-funded, investigator-driven and NIH network affiliated research, they will address the ACTG's specific scientific aims of translational research/drug development, optimization of clinical management and co-morbidities, PMTCT, prevention of HIV-1 infection and therapeutic vaccine development. This research will impact on the burden of HIV in southern Africa by focusing on prevention of new infections and optimizing care of those infected with HIV. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
4UM1AI069453-07
Application #
8415781
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Tauscher, Gail H
Project Start
2007-02-15
Project End
2013-12-09
Budget Start
2013-02-01
Budget End
2013-12-09
Support Year
7
Fiscal Year
2013
Total Cost
$2,591,933
Indirect Cost
$345,318
Name
Wits Health Consortium (Pty), Ltd
Department
Type
DUNS #
639391218
City
Johannesburg
State
Country
South Africa
Zip Code
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Dietrich, Janan J; Lazarus, Erica; Andrasik, Michele et al. (2018) Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS Behav 22:2312-2321
Ramteke, Sarah M; Shiau, Stephanie; Foca, Marc et al. (2018) Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc 7:143-150
Salazar-Austin, N; Kulich, M; Chingono, A et al. (2018) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav 22:569-579
Thiam-Diouf, Arame; Metch, Barbara; Sharpe, Cameron et al. (2018) Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine 36:1235-1242
Wall, Kristin M; Rida, Wasima; Haddad, Lisa B et al. (2017) Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries. Epidemiology 28:224-232
Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393
Bekker, Linda-Gail; Gray, Glenda E (2017) Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med 14:e1002241
Riddler, Sharon A; Husnik, Marla; Ramjee, Gita et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 12:e0178594
Hogg, Robert; Nkala, Busisiwe; Dietrich, Janan et al. (2017) Conspiracy beliefs and knowledge about HIV origins among adolescents in Soweto, South Africa. PLoS One 12:e0165087

Showing the most recent 10 out of 58 publications